Abstract-This work proposes a "learning-augmented clinical assessment" workflow to sequentially augment physician assessments of patients' symptoms and their socio-demographic measures with heterogeneous biological measures to accurately predict treatment outcomes using machine learning. Across many psychiatric illnesses, ranging from major depressive disorder to schizophrenia, symptom severity assessments are subjective and do not include biological measures, making predictability in eventual treatment outcomes a challenge. Using data from the Mayo Clinic PGRN-AMPS SSRI trial as a case study, this work demonstrates a significant improvement in the prediction accuracy for antidepressant treatment outcomes in patients with major depressive disorder from 35% to 80% individualized by patient, compared to using only a physician's assessment as the predictors. This improvement is achieved through an iterative overlay of biological measures, starting with metabolites (blood measures modulated by drug action) associated with symptom severity, and then adding in genes associated with metabolomic concentrations. Hence, therapeutic efficacy for a new patient can be assessed prior to treatment, using prediction models that take as inputs selected biological measures and physicians' assessments of depression severity. Of broader significance extending beyond psychiatry, the approach presented in this work can potentially be applied to predicting treatment outcomes for other medical conditions, such as migraine headaches or rheumatoid arthritis, for which patients are treated according to subject-reported assessments of symptom severity.
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I. Introduction

I
n diseases that are characterized by the complex phenotypes (traits) listed in Table 1 , such as psychiatric disorders, inflammatory diseases, and migraines, therapeutic/ treatment decisions are primarily based on the subjectreported/physician-rated severity of symptoms (which are an example of complex phenotypes/traits) in conjunction with standard social/demographic factors. The ability of these measures to predict therapeutic success is slightly better than chance [1] , [2] , and is largely limited by the lack of biological measures that reflect the underlying molecular mechanisms of therapeutic agents (e.g., drugs) and could therefore potentially serve as stronger predictors of therapeutic outcomes. The key contribution of this work in addressing that limitation is a "learning-augmented clinical assessment" workflow to sequentially augment physicians' assessments of subject-specific ratings of symptoms with heterogeneous biological measures (such as metabolomics and genomics) to significantly enhance the predictability of drug treatment outcomes as shown in Fig. 1 . As a case study, the workflow proposed in this work demonstrates improved predictability in antidepressant treatment outcomes of patients with major depressive disorder (MDD) by using biological measures (metabolomics and genomics) derived from peripheral blood to augment the severity measures and other sociodemographic factors currently used in clinical practice as predictor variables. This improvement in predictive accuracy of treatment outcomes motivates the need for developing antidepressant-specific prediction models, so that choice of antidepressant can be based on highest likelihood of remission of depressive symptoms. Choosing antidepressants that maximize therapeutic success marks a major shift from the current "try and wait" approach, which often requires multiple trials of antidepressants before patients achieve remission of their depressive symptoms.
To demonstrate the improved predictability in treatment outcomes, the workflow was developed using data from the clinical trial of the Mayo Clinic Pharmacogenomics Research Network Antidepressant Medical Pharmacogenomic Study (Mayo PGRN-AMPS) [7] , which is the largest single-center selective serotonin reuptake inhibitor (SSRI) trial that has been conducted in the United States. 603 patients completed the trial. They were administered citalopram/escitalopram (commonly prescribed SSRIs) for eight weeks, and psychiatric assessments of depression severity at baseline (pre-treatment), four weeks, and eight weeks were conducted by a clinician using the Quick Inventory of Depressive Symptomatology (QIDS-C). In this trial, biological measures for 290 of the 603 patients included genome-wide association study (GWAS) genotype data that, after imputation, included approximately 7 million single-nucleotide polymorphisms (SNPs) , Ĝ h and plasma metabolomic concentrations (B in Table 2 ) for 31 metabolites M h from patients at three time-points of the trial (at baseline, four weeks, and eight weeks). Through augmentation of those biological measures with psychiatric assessments and sociodemographic factors as predictor variables, the prediction accuracy of antidepressant treatment outcomes in MDD patients improved from 35% to 80% relative to the use of clinical measures alone as the predictor variables.
The formalism for integrating multiple biological measures in this case study is as follows and is illustrated in Fig. 2 . Just as tumor subtypes serve as a foundation for integrating biological measures in oncology, our formalism first established patient subtypes/stratification C by using mixture-model-based unsupervised learning techniques. In the first layer of overlaying of the biological measures, a set of metabolites m M ! were identified based on significant associations of their concentrations with symptom severity in previously inferred patient stratification. In the second layer of the overlay of biological measures, in what is referred to as a metabolomics-informed-genomics approach, we used GWAS to identify SNPs g G ! that are associated with concentrations of metabolites comprising . m Through iterative overlaying of biological measures starting with metabolites (blood measures reflecting drug action) associated with depressive severity, and then adding in the genes associated with metabolomic concentrations, the biological measures became more closely associated with the molecular mechanisms of antidepressant response. Finally, out of the more than 7 million possible predictor variables, the proposed approach identified about 65 predictor variables that comprised (1) SNPs ( ) g identified by the GWAS based on metabolomic concentrations, (2) metabolites ( ) m whose concentrations are significantly associated with depression severity in patient clusters, and (3) clinical measures (as shown in Table 2 ). Thus we made the size of the predictor data computationally tractable to predict clinical outcomes y u by using supervised learning methods ( , , , , ), m g S C y F where y is the treatment outcome labels of the training data.
The overarching significance of this work is suggested by the success of analogous "precision medicine" approaches in breast cancer therapeutics. Today, treatment strategies for each breast cancer patient are tailored to the tumor's specific molecular characteristics. That successful approach is facilitated by the close association of the phenotype (which is the molecular characteristics of the tumor, such as whether it is estrogenreceptor-positive (ER-positive), human-epidermal-growth-factor-receptor-2-amplified (HER2 amplified), and/or triple-negative) with a set of biomarkers, such as hormone receptors (e.g., ER), genes, and their SNPs, which, when taken together, can be prognostic of treatment outcomes [8] . However, in the study of treatment outcomes in patients with MDD (as for other diseases with complex phenotypes), some interesting key observations can be made. First, GWAS have often failed to associate SNPs with complex and non-binary phenotypes defined as, for example, "Did patients achieve a 50% reduction in baseline patient-reported/clinician-recorded symptoms?" As a consequence, it is acknowledged that methods of integrating widely heterogeneous biological measures without a priori biological knowledge become computationally intractable as the number of study variables increases to the order of millions [9] , [10] . Second, the predictability of antidepressant treatment outcomes when clinical measures alone are used is at best slightly better than chance [1] , [2] , [11] - [15] . Third, antidepressant medications such as selective serotonin reuptake inhibitors (SSRIs) are the standard of care for drug therapy in adults with MDD, but less than half of patients have favorable outcomes from this treatment [11] . In light of these observations, if learning techniques could more accurately predict treatment outcomes in patients with MDD by integrating a few biological measures prognostic of antidepressant treatment's success with routine clinical measures, the impact would be far-reaching, because MDD affects over 350 million patients worldwide and is expected to be the leading cause of disabilities globally by 2030 [16] - [18] . The approach proposed in this work will also have biological significance and clinical utility through further methodological innovations. For example, clusters inferred in this work can serve as the basis for using probabilistic graphical models to study the longitudinal behavior of depressive symptoms during antidepressant treatment; we have previously referred to such behavior as symptom dynamics [19] . From a clinical perspective, this method can be applied to other medical conditions as shown in Table 1 , such as rheumatoid arthritis and migraine headaches, for which patients are subtyped by the degree of swelling of their joints (which does not directly reflect a specific mechanistic biomarker), and by the pain ratings reported by patients using a scale similar to the QIDS-C scale that is used in this work to rate depressive symptoms [20] - [22] . Furthermore, the approach proposed in this work could also be used to augment biological measures with clinical measures in other psychiatric conditions, such as bipolar disorder and schizophrenia.
II. Related Work
Multi-omic integration has been broadly pursued in the context of precision medicine for which patients are subtyped by the underlying molecular characteristics of their disease.
A. Subtyping in Precision Medicine
Complexity in diseases is due to the manifestation of factors from both within and outside the genome. Alterations in many different molecular pathways may lead to similar disease phenotypes [23] . Therefore, where possible, disease subtypes can be defined by identifying different biological mechanisms that result in the same phenotypes. Such subtypes may present unique predispositions to benefit from different therapeutic options [24] . Hence, for the success of precision medicine initiatives for any disease, it is necessary to map therapeutic options to subtypes (phenotypes) by using molecular mechanisms of the therapeutic agent [24] . Until two decades ago, all breast cancers were treated in the same way, and the survival rate was much lower than it is today. However, with growing access to omics data from trials across the globe, it is now possible for breast oncologists to identify different kinds of tumor based on molecular characteristics, e.g., estrogen-receptor-positive (ER-positive), human-epidermalgrowth-factor-receptor-2-amplified (HER2 amplified), or triple-negative. Today, therapeutic options for breast cancer are tailored to those observed molecular characteristics of the tumor. As a result, the survival rate among patients with breast cancer has increased significantly [8] . Similar approaches have been taken for other aspects of oncology and also for autism, and are currently being explored for neurodegenerative diseases such as Alzheimer's disease [25] , [26] .
B. Multi-omics Integration
Integration of multi-modal biological data (multi-omics data) has been proposed in the context of breast cancer, diabetes, glioblastoma, and other diseases [9] , [27] - [31] . For example, imaging data have been combined with gene expression and patient demographics data to better predict the prevalence of cancer [31] . Such work has looked at identifying unique biological signatures or biomarkers from each of the types of static data, and then building a function that linearly or nonlinearly combines the data into a rule-based decision system [9] . Previous efforts have either used a sequential approach to integrate omics measures (assuming causal relationships) [32] , [33] or used simultaneous approaches when studying gene-gene interactions [34] . Another class of methods for integrating data have used network-based approaches that use correlation analyses as their foundation. Finally, based on knowledge of prior distributions in omics measures, Bayesian and knowledge-boosting approaches in both network and network-free approaches have been useful for incrementally growing the interactions between multi-omics measures [35] . For all these aforementioned approaches to be insightful and capable of handling the high-dimensional nature of multi-omics measures, a necessary condition is the availability of a priori biological knowledge of disease/patient subtypes or the phenotype [9] , [10] . In the absence of this a priori biological knowledge, handling large volumes of data with millions of features (e.g., 7 million SNPs across the whole genome in each patient) is computationally intractable [9] , [10] .
In addressing the limitations of the aforementioned work, this work makes significant contributions towards the integration of multi-omics measures for diseases with complex phenotypes, using MDD as a case study. 1) Although this work has not subtyped MDD patients by their molecular characteristics, replication of patient stratification for patients across independent trials with statistically identical symptom severity profiles is an important step forward in the field of psychiatry. The ability to replicate stratification is important given the widely acknowledged heterogeneity in depressive symptom profiles and drug response phenotypes [16] - [18] . 2) We assert that the stratification established in this work serves to overlay multiple biological measures that could potentially improve predictability of treatment outcomes.
3) We demonstrate that this approach to integrating multiomics measures provides mechanistic insights into drug response that can be experimentally established in clinical laboratories.
III. Data
The Mayo PGRN-AMPS trial (NCT 00613470) was designed to assess the clinical outcomes of adults (aged 18-84 years) with non-psychotic MDD after four and eight weeks of open-label treatment with citalopram or escitalopram and to examine the metabolomic and genomic factors associated with those outcomes [7] . Subjects were recruited from primary and specialty care settings in and near Rochester, MN from Table 2 . The social and demographic data ( ) S were assessed only at baseline. The treatment outcomes were established using the 16-item, clinician-rated version of the Quick Inventory of Depressive Symptomatology (QIDS-C) at baseline, four weeks, and eight weeks; the results comprise the clinical data C, which include the responses to the 16 QIDS-C questions and the total QIDS-C score of the symptom severity [36] . Biological measures for 290 of the 603 patients in this trial included GWAS genotype data that, after imputation, included approximately 7 million SNPs , Ĝ h and plasma metabolomic concentrations (B in Table 2 ) for 31 metabolites M h taken from patients at three time-points of the trial (at baseline, four weeks, and eight weeks). Samples were assayed on a high-performance liquid chromatography (HPLC) electrochemical coulometric array (LCECA) platform to obtain standardized measures of the concentrations of metabolites.
Clinical Definitions
Response is defined as a 50% reduction in baseline symptoms as measured at four weeks or eight weeks. If the total QIDS-C score measured at eight weeks is less than or equal to 5, then the patient is said to have achieved remission.
IV. Patient Stratification and Omics Association
A. Patient Stratification
Precision medicine in practice optimizes therapeutic options based on patient "subtypes" based on specific biological/clinical characteristics. Currently, there are no established mechanisms by which patients with MDD are subtyped/stratified at baseline (prior to treatment) or during the treatment, although at the end-point of the trial, patients are triaged into remitters, responders without remission, and non-responders. In the absence of predefined stratification of patients, as previously demonstrated in detail in our earlier work [19] , we use unsupervised learning to algorithmically infer patient clusters. Based on existing knowledge of gender differences in response to antidepressants [37] , the patients were stratified separately by gender.
observation
The p-value from the Shapiro-Wilk test of the total QIDS-C score from all three time-points of the trial, and in both men and women, was less than the significance level ( . ). 0 05 a = This meant that the symptom severity scores were not normally distributed, as we rejected the null hypothesis of the ShapiroWilk test (i.e., that the data are normally distributed).
approach
The fact that levels of symptom severity are not normally distributed meant that the k-means clustering algorithm would not be suitable as a clustering algorithm here. Without a loss in generality, under the assumption that the data (x; the total QIDS-C score, which is the sum of a group of individual depression items in the QIDS-C scale) were distributed as a mixture of Gaussians (modeled using a Gaussian mixture model (GMM)), we developed the patient stratification workflow (Algorithm 1). Starting with an assumption that the data have at least two components in the GMM, we used the expectation maximization (EM) algorithm to estimate the sufficient statistics parameters of the Gaussian components (mean n and variance ) 2 v of the GMM, as shown in Fig. 3(a) . 10,000 samples were randomly drawn from the inferred distributions (generateSamples). Next, the Kolmogorov-Smirnov test (ks.test) was used to test whether the distribution of the generated data was statistically similar to that of the original data. If the p-value ( ) p was less than the significance level ( . ), 0 05 a = then we rejected the null hypothesis that the two distributions were not similar. If that happened, the number of components was increased by one, and tested for similarity in the two distributions. Once we obtained the minimum number of components K in the GMM for which the generated and input data's distributions were similar, K clusters { ; : input: x ! total QIDs-C scores n of the components were the outputs of the workflow [38] . Patients were assigned to the component C that maximized the likelihood ( ) x L given the component's sufficient statistics (gmmCluster), as illustrated in Fig. 3(b) and described as
Results
At each time-point { t b ! (baseline), f (four weeks), e (eight weeks)}, we found three clusters of men and women by using the proposed stratification process. Clusters at the baseline are , , ,
= " , at four weeks are , , ,
= " , and at eight weeks are , , . C C C C e e e e 1 2 3
= " ,
The clinical value of the clustering behavior is that Ce 1 in both men and women captures all patients who achieved remission at the end of eight weeks. Furthermore, the Ce 2 in both men and women comprised patients who demonstrated response but did not achieve remission. Finally, patients in C f 3 (both men and women) did not exhibit response or achieve remission. The same workflow demonstrated identical patient stratification in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial [39] , i.e., the Kolmogorov-Smirnov test for the symptom severity scores between clusters of similar average symptom severity had a p-value . 0 8 2 [19] . From the analytics perspective, the significance of the replication of patient stratification in two independent clinical trials is that the clustering behavior followed the existing definitions of clinical outcomes in psychiatry.
B. Omics Associations
Baseline concentrations of key metabolites
, such as serotonin, kynurenine, tryptophan, tyrosine, and paraxanthine, were significantly correlated with depression severity in all three clusters at eight weeks. These correlations were biologically significant because they have been associated with MDD treatment and response, as these metabolites are related to the monoamine neurotransmitter pathways [40] , [41] . Furthermore,
, in the TSPAN5 (rs10516436), AHR (rs17137566), ERICH3 (rs696692), and DEFB1 (rs5743467, rs2741130, rs2702877) genes have been associated through use of GWAS with concentrations of kynurenine and serotonin [42] , [43] . The associations of these biological measures laid the foundation for assessing whether they could improve the predictability of clinical outcomes when combined with traditional clinical, social, and demographic variables.
V. Using Baseline Data to Predict Clinical Outcomes
A recent publication proposed a prediction model that uses elastic-net regularization for feature selection and a gradient boosting machine (GBM) for classification, but only using baseline social, demographic, and clinical data : S C 6 @ from the STAR*D trial [1] . While their prediction accuracies were better than chance, the authors acknowledged the limitations of their work, which suggests that it might be worthwhile to study whether the addition of baseline biological measures together with the social, demographic, and clinical data would increase the predictability of the clinical outcomes. With access to metabolomics and genomics data in a smaller cohort of the Mayo PGRN-AMPS trial, we set out to answer the following questions (illustrated in Fig. 4): 1) Would augmenting social, demographic, and clinical data : S C 6 @ with metabolomics data improve the prediction accuracies of treatment outcomes over using only social, demographic, and clinical data : S C 6 @ as predictor variables? 
Feature Selection and Choice of Classifiers
Three classes of classifiers are used in this work, including kernel, linear, and ensemble methods. For predicting outcomes using baseline clinical, social, demographic, and metabolomic data, we used support vector machines with linear kernels (SVMLinear) and support vector machines that use radial-basis kernels (SVM-RBF) as kernel methods [44] ; a generalized linear model (GLM) as a linear method [45] ; and GBMs as an ensemble method [46] . As the creators of those methods have indicated, each of those broader types has its own merits, mathematical nuances, and complexities, and all of them have been used in other classification applications, such as in Kaggle [47] .
To use all of the omics and clinical, social, and demographics data to predict outcomes, we used nonparametric classifiers such as SVM-RBF and random forests, as they are better suited to handling correlated features [48] , and have been used in predicting treatment outcomes in other psychiatric diseases such as schizophrenia.
In addition to elastic-net regularization, recursive feature elimination (i.e., a wrapper method) was also used for the GLM and GBM classifiers; that made it possible to estimate the model performance not only by optimizing the parameters of the model, but also by searching for the right set of predictor variables. Based on our datasets, the prediction performance did not significantly vary with or without the use of any of the feature selection methods; the prediction accuracy remained within 4%. This observation could also be in part due to a reasonably small size of predictor variables.
To minimize the effects of overfit and information leak, nested cross-validation (nested-CV) with 5 repeats was used to train the classifiers. In each repeat, data were randomized, and the nested-CV comprised an outer loop and an inner loop. The outer loop had a fivefold cross-validation to split the data into training data (80% of the data) and testing data (the remaining 20%). The inner loop used the training data to train the classifier by using a tenfold cross-validation, and the trained classifier was tested on the testing data. To minimize the effects of class imbalance (i.e., unequal numbers of responders (60%) and nonresponders (40%)) in the training data, we used the synthetic minority over-sampling (SMOTE) algorithm [49] , which simulated patient profiles of the under-sampled class and up-sampled the under-sampled class to ensure that the two classes had equal sizes. Prediction performance was reported using several metrics (AUC, sensitivity, and specificity), and the statistical significance of the classifier's accuracy was established using the
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Predictive Models Predictive Models Predictive Models Accuracy Accuracy Accuracy Improvement? Improvement? null information rate (NIR, which is the prevalence of the class with the largest samples) that served as a proxy for chance.
Training with and Without Biological Measures
In order to quantitatively assess the benefit of adding biological measures to predict outcomes , y u we trained classifiers ( , , , , ) m g S C y F using (1) baseline clinical data that included only social and demographic data,
[ : ]; X S C = (2) all baseline data (including metabolomics and genomics data),
; B m g = and (3) training labels y for treatment outcomes. Metabolites ( ) m whose baseline concentrations were correlated with the symptom severity at eight weeks, and SNPs ( ) g associated with their concentrations, were then normalized along with clinical data in order to train the chosen supervised learning methods. It is important to note that several other researchers have proposed the combination of other modalities of biological data [28] - [30] , but it remains to be explored whether combination becomes less effective when patient-reported data are used, since there is considerable heterogeneity in subject-reported measures. Therefore, to the best of our knowledge, this is the first time that quantified biological measures comprising metabolomics and genomics measures have been integrated for analyses with the clinical measures of psychiatric assessments that comprise demographic data and patientprovided responses to symptom questionnaires (such as QIDS-C). For all the classifiers, we compared the AUC, in addition to the generalized prediction accuracies, to see whether the same model's predictive ability improved with the addition of metabolomics data. Further, if the predictability improved, we extracted the top five predictors of the model that provided the best balance of accuracy and AUC to see whether the top predictors were dominated by the metabolomics.
A. Results
As shown in Table 3 , for both men and women and for both the outcomes response and remission, there was a 30% improvement in the overall accuracy and corresponding AUC. The highlighted columns in Table 3 indicate the best-performing models with the metabolomics data included; four out of the top five predictors are metabolites, indicating that their addition to the prediction model likely explains the increase in the predictability of the outcomes. As shown in Table 4 , there was a further improvement of at least 5% in the AUC and corresponding accuracy when genomics data were integrated with the metabolomics, clinical, social, and demographic data. We have two observations about the inclusion of biological measures in all these predictions. First, the top predictors of outcomes when biological measures were used were different in men and women, likely pointing to different biological mechanisms determining how men and women respond to the same antidepressant. Second, except for the variable seasonal pattern and the involvement item in the QIDS-C scale, no other clinical/demographic measures were predictive of outcomes. Finally, it is biologically significant that many of the top predictor metabolites identified in this work are known to be correlated with mood in the behavioral sciences, which has additional promising implications, as discussed next.
VI. Broader Significance
The approach presented in this work provides opportunities for further methodological extensions and innovations that will allow for longitudinal analyses of therapeutic agents (such as the analysis done for antidepressants in this work). Our work also has broader clinical significance based on knowledge gained through the analyses conducted in this work.
A. Methodological Extensions
Patient stratification across the time-points of a clinical trial could serve as the intelligence needed to build a probabilistic graph in which stratification could be used as the nodes of the graph, so that one can study the longitudinal effects of therapeutic agents during treatment. By using the proportions of patients who traverse between clusters of consecutive timepoints (transition probabilities), we can use optimizations such as the Viterbi algorithm or forward algorithm to establish the "most likely" paths that patients will traverse during the treatment. Our previous work has demonstrated this capability by using factor graphs to formalize the depressive symptom severity data during the antidepressant treatment's timeline, and then using the forward algorithm to establish the "most likely" paths (referred to as symptom dynamics) that patients will traverse based on changes in their depression severity during treatment [19] .
B. In Psychiatry
Patient stratification conforming to known psychiatric definitions of outcomes, and replicated in both the Mayo PGRN-AMPS and STAR*D trials, provided the first show of confidence in our ability to model symptom responses to citalopram/escitalopram (antidepressant) treatment in depressed patients. Our previous work demonstrated its biological significance through its improvement of predictability by integrating metabolomics data with clinical measures, because metabolites, such as serotonin and kynurenine, were among the top predictors [19] . That development was important because for decades, the treatment of MDD has focused on biogenic amine neurotransmitter pathways, i.e., the synthesis and metabolism of catecholamines (such as norepinephrine) and indoleamines (such as serotonin) [40] , [41] . Furthermore, the existing body of knowledge fits well with the findings of our study; note that the metabolites listed in Table 3 include serotonin (5HT) itself as well as two metabolites from the competing tryptophan metabolism pathway (KYN and 3OHKYN) and the major catecholamine metabolite (MHPG), which are known to play a role in behavior.
The addition of genomics data with metabolomics and clinical measures as predictor variables has further improved the predictability of antidepressant outcomes, as shown in Table 4 . This result raises the question of whether the genes associated with serotonin and kynurenine are also extending their effects in other metabolites used in this study through other mechanisms. The improvement in predictability should motivate researchers and clinicians to collect more biological measures for psychiatric diseases other than major depressive disorder (e.g., bipolar disorder, schizophrenia, and various dementias) that would not only help subtype or stratify patients by their symptom severity profiles, but also combine biological characteristics that would enable treatment strategies closer to the kinds used in breast cancer therapeutics.
C. In Pharmacogenomics Research
Pharmacogenomics research focuses on understanding the interplay between drug effects and functions of the genome. In this context, we reflect on the improvements in breast cancer therapeutics wherein treatment selection is based on molecular characteristics of the tumor. In diseases such as major depressive disorder, for which such biologically based subtyping is not possible, the approach described in this work for stratifying patients using symptomatic characteristics is of immense value to associated pharmacogenomics research. In particular, trials could be designed in which multi-omics (metabolomics, genomics, etc.) and other biological measures (neuroimaging, electrophysiology, etc.) could be collected that help to establish biological associations with patients stratified using the proposed approach. Then, longitudinal effects of the drug on these biomarkers can be used to study why patients either respond well to the intervention or do not. Furthermore, as already demonstrated in this work, associations of biological markers with inferred patient stratification can provide improved predictability for treatment outcomes.
TAblE 3
Clinical outcome prediction performance with metabolomics data in the Mayo Clinic PGRN-AMPS trial. Expansions of the abbreviations of the top predictors are as follows. ATOCO is (+)-alpha-tocopherol; URIC is uric acid; QIDSC-1 is sleep-onset insomnia [36] ; KYN is kynurenine; 3OHKY is 3-hydroxykynurenine; AMTRP is alpha-methyltryptophan; I3PA is indole-3-propionic acid; GTOCO3 is (+)-gamma-tocopherol (redox state #3); 5HT is serotonin; MHPG is methoxy-hydroxyphenyl glycol; MET is methionine; QIDS-13 is involvement [36] ; HGA is homogentisic acid; PARAXAN is 1,7-dimethylxanthine. 
MEn
D. In Other Clinical Applications
From a biological mechanistic perspective, on one end of the clinical spectrum there are diseases such as breast cancer for which treatment is based on tumor subtypes. At the other end of the spectrum are neuropsychiatric diseases such as MDD for which subtyping of individual patients is possible based on their reported symptom severity, as demonstrated in this work. Between these two extremes are migraine headaches and inflammatory diseases, such as rheumatoid arthritis (RA), in which patients are subtyped by the degree of swelling of their joints (which does not directly reflect a specific mechanistic biomarker) and by pain ratings reported by the patients using validated scales that are similar to the QIDS-C scale used to rate depressive symptoms in this work [20] - [22] . Therefore, there is sufficient heterogeneity in RA symptoms to make treatment response phenotypes so complex that the methodological innovation presented in this work could be used to overlay biological measures that provide a significant mechanistic perspective. This approach could then be tested for the prediction of outcomes in response to the drug therapy for migraine headaches or RA, as additional examples of a possible broader application of the approach described here.
VII. Conclusions, Limitations, and Future Work
Use of data-driven approaches such as the one proposed in this work provides a way to identify and combine a small set of targeted biological measures to augment physician assessments to accurately predict clinical outcomes for new patients prior to initiating treatment. Use of such a small set of measures (as opposed to millions of variables, as with genome-wide genotype data) makes inference of novel biology, or accurate prediction of clinical outcomes in diseases with complex phenotypes, computationally tractable. Of further significance is the ability to replicate patient stratification in independent clinical trial datasets while also having clinical validity in the context of studying antidepressant response in patients with major depressive disorder. The stratification that serves as the basis for sequential overlaying of biological measures has not only improved the predictability of antidepressant outcomes, but also shown that top predictors have mechanistic associations with antidepressant response. These findings together motivate the use of this approach for other common diseases, such as rheumatoid arthritis or migraine headaches, for which a similar complexity in phenotype is seen, and will also motivate researchers and clinicians to collect additional biological measures for other psychiatric diseases for which the methods proposed in this work could identify novel mechanisms of therapeutic efficacy. Furthermore, the workflow could be further enhanced by considering other omics data such as transcriptomics, and/or proteomics, in addition to profiling of the microbiome. While the work has shown promise in our ability to combine multiple biological measures, our future work will focus on establishing replicability of the findings in external datasets of MDD patients treated with citalopram/escitalopram and other antidepressants. Such replication in findings would represent a strong foundation for investigating biological factors associated with pathophysiology of this disease with heterogeneous disease states, and additional mechanisms of drug action.
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